Quantcast
Last updated on April 25, 2014 at 5:25 EDT

Dehaier Medical Develops New Proprietary High-Efficiency Oxygen Inhaler

June 14, 2012

BEIJING, June 14, 2012 /PRNewswire-Asia-FirstCall/ — Dehaier Medical Systems Ltd. (NASDAQ: DHRM) (“Dehaier” or the “Company”), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has co-developed its “High-Efficiency Oxygen Inhaler” with Dr. Ding Jianzhang of Beijing Haidian Hospital, which is expected to begin selling in the third quarter of 2012 in mainland China. The portable device is designed for use in homecare oxygen therapy, emergency treatment, disaster relief activities and high-altitude settings.

(Photo: http://photos.prnewswire.com/prnh/20120614/CN24727 )
(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO )

Dr. Ding Jianzhang, the author of “Oxygen Therapeutics & Health”, has over 30 years experience, specializing in hyperbaric oxygen treatment. In 2003, he received a patent for an atmospheric oxygen therapy mask. Dehaier obtained an exclusive license to Dr. Ding’s patent and has re-designed, developed and used this patent to create the High-Efficiency Oxygen Inhaler. The Inhaler is easily portable and features instantaneous high volume oxygen delivery, while also reducing waste through its uniquely triggered oxygen conveying system. The system supplies oxygen volume automatically according to patient lung capacity and delivers oxygen only on inhalation. The Company is going to apply a patent on its design and technology of this newly-developed High-Efficiency Oxygen Inhaler from the China Patent and Trademark office.

Dehaier Medical’s CEO, Mr. Ping Chen commented, “We continue to devote our research and development efforts toward markets where we feel there is a distinct need. After a thorough review, we felt that a portable and efficient solution for individuals with severe oxygenation failure or cerebrovascular disease (blood circulation to the brain) would improve their standard of living and fill a distinct niche in China’s medical homecare market. In addition, we expect that our new inhaler will be attractive to athletes such as mountain climbers, emergency rescue personnel and others who need portable and convenient oxygen solutions. We are proud to provide the state of art High-Efficiency Oxygen Inhaler to the market, which again represents our business growth strategy of diversifying sales through shifting focus to homecare medical segment and enriching the product line of home oxygen therapy services. We look forward to realizing considerable sales from the product in near future.”

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier’s technology is based on six patents and five software copyrights; additionally Dehaier has two pending software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn.

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular statements about Dehaier’s newly developed High-Efficiency Oxygen Inhaler. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact Us

Dehaier Medical Systems Limited
Surie Liu
+86 10-5166-0080
lius@dehaier.com.cn

Dehaier Medical Systems Limited
Tina He
+86 10-5166-0080
hexw@dehaier.com.cn

The Equity Group Inc.
Katherine Yao
+86 10-6587-6435
kyao@equityny.com

In America

The Equity Group Inc.
Adam Prior
(212) 836-9606
aprior@equityny.com

SOURCE Dehaier Medical Systems Ltd.


Source: PR Newswire